GÖRG advises Medigene AG on a capital increase with gross issue proceeds of EUR 5.9 million

München, 16.05.2024

GÖRG Partnerschaft von Rechtsanwälten mbB, under the lead management of Munich partner Dr Bernt Paudtke, advised Medigene AG on a capital increase with gross proceeds of EUR 5.9 million. 

Medigene AG is a biotechnology company founded in 1994 and listed on the stock exchange since 2000 with its headquarters in Martinsried near Munich and a US office in San Diego, California. The company develops highly innovative immunotherapies for the treatment of solid cancer tumours. Medigene focuses on differentiated T-cell-targeted therapeutic approaches.

The capital increase resolved on 22 April 2024 led to the issue of 4,912,531 new shares and an increase in the total number of shares to 29,475,189. 4,152,247 of the newly created shares were subscribed by shareholders as part of the rights offering. This corresponds to a subscription ratio of 84.52%. In addition, 760,284 new shares were placed with European investors. Members of the Executive Board and Supervisory Board of Medigene AG also participated in the capital increase. Following the entry of the capital increase in the commercial register of the Munich Local Court, the Company's new share capital amounts to EUR 29,475,189.00.

Medigene AG achieved a gross inflow of funds of around EUR 5.9 million with the capital measure. The transaction proceeds will serve the biotech company as a basis to advance the clinical development of the main programme MDG1015 and at the same time to enter into new partnerships in order to expand the end-to-end platform to further therapeutic approaches.

Medigene AG once again relied on the proven transaction team led by GÖRG partner Dr Bernt Paudtke for the capital increase. The law firm has already provided legal advice to the biotech company on several occasions in connection with capital measures. CapSolutions GmbH and MC Services AG also participated in the transaction as bookrunners. Baader Bank AG was responsible for the technical implementation of the capital increase.

Advisors Medigene AG

GÖRG Partnerschaft von Rechtsanwälten mbB
Dr Bernt Paudtke ( Lead Partner, Stock Corporation and Capital Markets / Corporate Law, Munich)
Dr Lutz Pospiech (Partner, stock corporation and capital markets law / corporate law, Munich)
Dr Stefan Heyder (Partner, Corporate Law, Munich)
Tobias Reichenberger (Associated Partner, Stock Corporation and Capital Markets / Corporate Law, Munich)

 Newsletter Icon

We inform you about current legal developments in the areas relevant to you.

Subscribe to our Newsletter


Einige der von uns gesetzten Cookies dienen dazu, bestimmte Funktionen unserer Webseiten zu ermöglichen, insbesondere zur Steuerung des Cookie-Banners (damit dieses bei Ihren erneuten Besuchen nicht immer wieder angezeigt wird). Diese Cookies enthalten keine personenbezogenen Daten, insbesondere nicht Ihre IP-Adresse. Andere Cookies, die zu Analysezwecken gesetzt werden (siehe hierzu auch den Abschnitt „Web-Analyse-Tools“), helfen uns zu verstehen, wie Besucher mit unseren Webseiten interagieren. Diese Cookies dienen dazu, die Nutzung unserer Webseiten statistisch zu erfassen und zum Zwecke der Optimierung unseres Angebotes auszuwerten. Die Analyse-Cookies werden bis zu 13 Monate gespeichert.

Save Cancel OK Deny tracking Privacy policy